insights_auto
Why is CMPS up 5.61%?
Dive Deeperchevron_right
CMPS:NASDAQ
Compass Pathways PLC
$11.67
arrow_upward
+5.61%(+0.62) 1D
Oct 27, 12:56:54 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CMPS...
Open
$11.10
High
$11.80
Low
$11.00
Mkt. cap
1.62B
Avg. vol.
2.70M
Volume
977.77K
52-wk high
$15.87
52-wk low
$4.88
EPS
-$3.47
Beta
2.55
Shares outstanding
138.48M
No. of employees
156
Open
$11.10
High
$11.80
Low
$11.00
Mkt. cap
1.62B
Avg. vol.
2.70M
Volume
977.77K
52-wk high
$15.87
52-wk low
$4.88
EPS
-$3.47
Beta
2.55
Shares outstanding
138.48M
No. of employees
156
News stories
From web sources and news partners
Yahoo Finance
·
6 hours ago
Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026
Investing.com
·
21 hours ago
B.Riley reiterates Buy on Compass Pathways stock, $22 target
Investing.com India
·
21 hours ago
B.Riley reiterates Buy on Compass Pathways stock, $22 target By Investing.com
Business Insider
·
2 days ago
After a long, strange trip, this CEO is close to taking a psilocybin pill to market
Profile
Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, has completed phase 3 clinical trials for treatment-resistant depression. The results showed clear benefit to participants as measured on the MADRS depression rating scale. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine.
Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Wikipedia
About Compass Pathways PLC